The radiotherapy with methotrexate, vinblastine, doxorubicin,and cisplatin treatment is an effective therapeutic optionin patients with advanced or metastatic bladder cancer

Journal of Radiation Research

Volumn 52, Issue 5, 2011, Pages 674-679

  Ikeda, Masaomi ^a   Matsumoto, Kazumasa ^a   Niibe, Yuzuru ^a   Satoh, Takefumi ^a   Fujita, Tetsuo ^a   Iwamura, Masatsugu ^a   Ishiyama, Hiromichi ^a   Kotani, Shoko ^a   Hayakawa, Kazushige ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DISEASES;

BLADDER CANCERS; CIS-PLATIN; CISPLATIN; COMPLETE RESPONSE; DOXORUBICIN; EXTERNAL BEAM RADIATION THERAPY; OVERALL SURVIVAL; RADIATION FIELD; TOTAL DOSE; VINBLASTINE;

RADIOTHERAPY;

EID: 80053345332     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.11036     Document Type: Article

References (24)

1. Sternberg CN, et al (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461-469.
2. Sternberg CN, et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 64: 2448-2458.
3. Loehrer PJ, et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066-1073.
4. Pollack A and Zagars GZ (1996) Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 14: 86-95.
5. De Neve W, et al (1995) Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 36: 183-188.
6. Mothersill C, et al (1990) The effect of radiation and cytotoxic platinum compounds on the growth of normal and tumour bladder explant cultures. Acta Oncol 29: 179-184.
7. Kaufman DS, et al (2009) Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73: 833-837.
8. Hagan MP, et al (2003) RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57: 665-672.
9. Rodel C, et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061-3071.
10. Kaufman DS, et al (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5: 471-476.
11. Chauvet B, et al (1996) Concurrent cisplatin and radiotherapy for patients with muscle-invasive bladder cancer who are not candidates for radical cystectomy. J Urol 156: 1258-1262.
12. Coppin CM, et al (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 14: 2901-2907.
13. Tester W, et al (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25: 783-790.
14. Shipley WU, et al (1987) Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935.
15. Shipley WU, et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16: 3576-3583.
16. Wallmeroth A, et al (1999) Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): an autopsy study on 367 patients. Urol Int 62: 69-75.
17. Lin CC, et al (2009) Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 75: 442-448.
18. Goldie JH and Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733.
19. Kennedy KA (1987) Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des 2: 181-194.
20. Basavaraju SR and Easterly CE (2002) Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys 29: 2391-2403.
21. Bentzen SM, Harari PM and Bernier J (2007) Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4: 172-180.
22. von der Maase H, et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608.
23. von der Maase H, et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18: 3068-3077.
24. Arias F, et al (2000) Chemoradiotherapy for muscle-invading bladder carcinoma: final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47: 373-378.